Next Article in Journal
The French Armed Forces Virology Unit: A Chronological Record of Ongoing Research on Orthopoxvirus
Next Article in Special Issue
HIV-1 Subtypes and 5’LTR-Leader Sequence Variants Correlate with Seroconversion Status in Pumwani Sex Worker Cohort
Previous Article in Journal
Biology of Porcine Parvovirus (Ungulate parvovirus 1)
Previous Article in Special Issue
Characterization of HIV-1 Near Full-Length Proviral Genome Quasispecies from Patients with Undetectable Viral Load Undergoing First-Line HAART Therapy
Article Menu

Export Article

Open AccessReview
Viruses 2018, 10(1), 1; doi:10.3390/v10010001

HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment

1
International Center for Research in Infectiology, Retroviral Oncogenesis Laboratory, INSERM U1111—Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, F-69007 Lyon, France
2
Equipe labellisée “Ligue Nationale Contre le Cancer”, France
*
Author to whom correspondence should be addressed.
Received: 30 November 2017 / Revised: 16 December 2017 / Accepted: 18 December 2017 / Published: 21 December 2017
(This article belongs to the Special Issue Homage to Mark Wainberg)
View Full-Text   |   Download PDF [909 KB, uploaded 21 December 2017]   |  

Abstract

Going back to their discovery in the early 1980s, both the Human T-cell Leukemia virus type-1 (HTLV-1) and the Human Immunodeficiency Virus type-1 (HIV-1) greatly fascinated the virology scene, not only because they were the first human retroviruses discovered, but also because they were associated with fatal diseases in the human population. In almost four decades of scientific research, both viruses have had different fates, HTLV-1 being often upstaged by HIV-1. However, although being very close in terms of genome organization, cellular tropism, and viral replication, HIV-1 and HTLV-1 are not completely commutable in terms of treatment, especially because of the opposite fate of the cells they infect: death versus immortalization, respectively. Nowadays, the antiretroviral therapies developed to treat HIV-1 infected individuals and to limit HIV-1 spread among the human population have a poor or no effect on HTLV-1 infected individuals, and thus, do not prevent the development of HTLV-1-associated diseases, which still lack highly efficient treatments. The present review mainly focuses on the course of HTLV-1 infection, from the initial infection of the host to diseases development and associated treatments, but also investigates HIV-1/HTLV-1 co-infection events and their impact on diseases development. View Full-Text
Keywords: HTLV-1; HIV-1; viral transmission; ATLL; TSP/HAM; treatments HTLV-1; HIV-1; viral transmission; ATLL; TSP/HAM; treatments
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Futsch, N.; Mahieux, R.; Dutartre, H. HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment. Viruses 2018, 10, 1.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top